Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabotamig - Arbele

Next Previous
Drug Profile

Cabotamig - Arbele

Alternative Names: ARB-202

Latest Information Update: 09 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arbele
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulins; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer
  • Preclinical Biliary cancer

Most Recent Events

  • 09 Aug 2023 ARB 202 is still in phase I trials for Liver cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Hong Kong (Parenteral)
  • 02 Aug 2023 Pharmacokinetics data from a phase I trial in Liver cancer, Gastrointestinal cancer, Gastric cancer, Colorectal cancer Cholangiocarcinoma, Pancreatic cancer released by Arbele
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Liver-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Hong Kong (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top